Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Hye Kyung | - |
dc.contributor.author | Cho, Eun Ju | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Hong, Young Mi | - |
dc.contributor.author | Kim, Soon Sun | - |
dc.contributor.author | Kim, Hwi Young | - |
dc.contributor.author | Heo, Nae-Yun | - |
dc.contributor.author | Park, Jung Gil | - |
dc.contributor.author | Sinn, Dong Hyun | - |
dc.contributor.author | Kang, Wonseok | - |
dc.contributor.author | Jeong, Song Won | - |
dc.contributor.author | Song, Myeong Jun | - |
dc.contributor.author | Park, Hana | - |
dc.contributor.author | Lee, Danbi | - |
dc.contributor.author | Lee, Yong Sun | - |
dc.contributor.author | Cho, Sung Bum | - |
dc.contributor.author | An, Chan Sik | - |
dc.contributor.author | Rhee, Hyung Jin | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Lee, Jeong-Hoon | - |
dc.contributor.author | Yu, Su Jong | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Kweon, Young Oh | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Cho, Mong | - |
dc.contributor.author | Cheong, Jae Youn | - |
dc.contributor.author | Park, Seung Ha | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Korean TACE Study Group | - |
dc.date.available | 2020-12-09T08:53:53Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 0163-2116 | - |
dc.identifier.issn | 1573-2568 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/33950 | - |
dc.description.abstract | Background and Aims The influence of direct-acting antivirals (DAAs) on chronic hepatitis C (CHC)-related hepatocellular carcinoma (HCC) remains controversial. We investigated the effect of eradicating CHC using DAAs on treatment outcomes in patients with CHC-related HCC treated with transarterial chemoembolization (TACE). Methods This nationwide, multi-center, retrospective study recruited patients with CHC-related HCC treated with TACE as the first-line anti-cancer treatment, and who achieved a sustained virological response (SVR) using DAAs (DAA group) between 2006 and 2017. Patients achieving an SVR following interferon-based treatment (IFN group) and those without treatment (control group) were also recruited for comparison. Results A total of 425 patients were eligible for the study. Of these, 356 (83.8%), 26 (6.1%), and 43 (10.1%) were allocated to the control, IFN, and DAA groups, respectively. A multivariate analysis showed that liver cirrhosis, segmental portal vein thrombosis, and larger maximal tumor size independently predicted an increased risk of progression (all p < 0.05), whereas, the DAA group (vs. IFN and control groups) independently predicted a reduced risk of progression (hazard ratio (HR) = 0.630, 95% confidence interval 0.411–0.966, p = 0.034). The cumulative incidence rate of HCC progression in the DAA group was significantly lower than that in the IFN and control groups (p = 0.033, log-rank test). In addition, the DAA group (vs. IFN and control groups) was independently associated with a reduced risk of mortality (p = 0.042). Conclusions DAA treatment provided significantly prolonged progression-free survival in patients with CHC-related HCC treated with TACE compared to that in patients administered IFN or no treatment. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Kluwer Academic/Plenum Publishers | - |
dc.title | Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1007/s10620-020-06533-7 | - |
dc.identifier.scopusid | 2-s2.0-85089894151 | - |
dc.identifier.wosid | 000564954900001 | - |
dc.identifier.bibliographicCitation | Digestive Diseases and Sciences, v.66, no.7, pp 2427 - 2438 | - |
dc.citation.title | Digestive Diseases and Sciences | - |
dc.citation.volume | 66 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 2427 | - |
dc.citation.endPage | 2438 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | RIBAVIRIN | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Hepatitis C virus | - |
dc.subject.keywordAuthor | Direct-acting antiviral | - |
dc.subject.keywordAuthor | Transarterial chemoembolization | - |
dc.subject.keywordAuthor | Progression | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.